the abcellera biologics ( acc ) company is a new and promising industry industry that is a leading industry in the united states and the world. it is a new technology technology that is based on partnerships that are centered around partnerships. we have developed a unique business model that can accelerate drug discovery across the industry. we have developed a unique business strategy that can accelerate drug discovery across the industry, and we believe that this is best done in a partnership model. we have successfully successfully acquired trianni and also made significant investments in facilities and equipment to strengthen our team and technology platform. we ended the year with nearly $600 million in cash and over 200 million in accounts receivable. this provides a strong cash position which we will execute our plan for future growth.